M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Idera Pharmaceuticals, Inc. to acquire Aceragen
Announced Sep 28, 2022 · Closed Sep 28, 2022 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock
Transaction
- Acquirer
- Idera Pharmaceuticals, Inc.
- Target
- Aceragen
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Sep 28, 2022
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Not disclosed
- To the target
- Wedbush
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)